In certain ovarian cancer cells, the noted growth inhibitory effects of EHZ2 inhibition are attributed to increased levels of phosphoinositide-3-kinase interacting protein 1(PIK3IP1) which antagonizes the cell survival signaling [132]. This evidence concerns the gene PIK3IP1 and ovarian cancer.